List of Contract Manufacturing Companies in India - 30

Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health. Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement. At Aragen, we recognize your work is vital, urgent and impacts lives. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.

Beta Drugs Ltd. is a dedicated world leader in oncology. BDL is a Global leader in the development of enabling products, scientific knowledge, and technical expertise within a wide range of applications. At Beta DrugsLtd. (BDL.) we are improving both the speed to market of our products and the value of our product introductions to customers. Inspired by a newly-formed breakthrough innovation group, Beta Drugs Ltd. (BDL.) is actively exploring opportunities that stretch business and technology boundaries.

Established in 2002 into API manufacturing, we have a consolidated position in the domestic and global market for the API Business. In today's dynamic global pharmaceutical market, we at BDR Pharmaceuticals have carved a niche for ourselves, with our formulations portfolio for specialty medication. Our unique strategy of multi-branding ensures that critical and lifesaving medicines are available at affordable prices with two API and formulation facilities at Gujarat, Uttarakhand and a pellet facility at Hyderabad.

Biodeal Pharma is a WHO-GMP Certified and PIC/S approved pharmaceutical manufacturing Company and is a highly respected name as a fully integrated Indian Manufacturing Company located amidst the green fields of Himachal Pradesh and are leading global providers in Pharmaceuticals, Cosmetics and Nutraceuticals. Owing to persistent values of customer satisfaction, unsurpassed quality standards, human safety, innovation and serves a clientele of more than 30 reputed companies like TORRENT, DRL, SUN PHARMA, DR. MOREPEN, CADILA, ZYDUS, ALEMBIC, ALKEM, WOCKHARDT, INTAS, ZUVENTUS, IPCA, INDOCO, MACLEODS , KOYE PHARMA, ERIS LIFESCIENCES , AJANTA PHARMA, etc. BIODEAL offers Products on Third Party Basis for Export as well as Domestic business on contract manufacturing basis. Our Sections:- • Tablets (Drugs & Nutraceuticals) • Capsules (Drugs & Nutraceuticals) • Dry Powder Inhaler Capsules • Oral Spray (Food) • Dry Sachet • Dusting Powder • Nasal Sprays • Lotion • Ointment • Cosmetics Biodeal has a strong presence in NUTRACEUTICALS with VITAGEN, offering Vitamins, Multi complex, Antioxidants, Amino acids, Omegas, Herbals and varied categories to meet specific needs. Besides most common tablet or capsule formats, VITAGEN offers the biggest range of innovative delivery forms which are easy to consume and have a great taste, e.g., Spray, Chewable, Sachets. The large number of bioavailable and well absorbed products provides the opportunity for everyone to be able to get a Nutrition therapy according to individual needs. Also introducing all new range of VITAGEN Sunscreens, specifically developed formulations for sun protection and skin care. Vegetarian prebiotic capsule is used in all the products, which are generally better consumed by digestive system, and ideal for those who do not want to take animal gelatin for moral, diet or religious reason, as well as opting for a healthier alternative.

Biophore is a research driven global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) having its operations based in Hyderabad, India and also has a registered office in New Jersey, USA. Biophore has two dedicated R&D facilities in Hyderabad and Vishakapatnam. The research facilities are fully equipped with wide range of R&D and process equipment from USA with reaction capabilities from milligram to kilogram. Ever since its establishment in 2007, Biophore recognized that there were two ways of growing the API business: manufacture a large API product basket, or pick a handful of promising APIs in select therapeutic categories and grow them over the long-term. Biophore consciously chose the latter option and focused on not only building competencies and adding scale in those segments but more importantly, building efficiencies that would make it an undisputed leader in these products of choice. The product range is constantly expanded through its own R&D, process development, technology transfers, joint ventures and collaborations. Biophore's core strength lies in development of non – infringing routes for comprehensive range of bulk actives and intermediates, development of niche APIs, oncology APIs, APIs for MRI contrast agents and APIs for NCE - 1 filing. Biophore has made strategic investments in two manufacturing facilities. Sionc pharmaceuticals & Azico – Biophore, Both located at Vishakapatnam. Among them Sionc, a multi-purpose plant has passed FDA inspection in 2013 & 2016 with no observations on the Form 483. This is the reason to be proud and confirmation of the highest quality standards of Biophore. Our other facility Azico – Biophore is also a n FDA approved facility that strictly complies with cGMP procedures and maintains well documented SOPs, with a modern quality control laboratory thereby ensuring the production of highest quality APIs.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last seven decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia. For more information visit: https://www.cadilapharma.com/

Calyx Chemicals & Pharmaceuticals Ltd. is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, based in India. With over 40 years of experience, the company operates a US FDA-inspected facility in Tarapur, Maharashtra. It specializes in APIs for anti-TB and anti-malarial therapeutic areas and offers custom synthesis of pharmaceutical intermediates. Calyx provides integrated services through its Contract Research and Manufacturing Services (CRAMS), which encompass API development and contract manufacturing. The company has a strong regulatory compliance record, having successfully passed audits from USFDA, EDQM, and WHO. It serves a global customer base, focusing on regulated markets such as the US and Europe.

Centaur Pharmaceuticals ranks among India’s few, fully integrated pharmaceutical firms with proficiencies across the pharmaceutical value chain. Centaur leverages its synergies across API, R&D, CRAM, Clinical Research and formulations to provide end-to-end solutions to prestigious pharmaceutical partners.

Century Pharmaceuticals Ltd is a privately held Pharmaceutical Company based out Vadodara, India. For more than 30 years, we have emerged as a respectable name in the industry. Our services include manufacturing APIs, facilities for contract manufacturing, Biotechnology research, API research, stability studies, and more.

Epygen Biotech private limited is a Biotechnology organization promoted by the founders of Epygen Labs, bringing along decades of precious experience in Biotech research and successful business. With offices, labs and manufacturing facilities in Dubai, India and USA, Epygen Biotech exhibits unique capabilities in the Biotechnology field, where it has developed a strong pipeline of therapeutic proteins for Cardiovascular, Oncology and Immune disorders. With focus on Biosimilars and Novel Biologic Entities, Epygen utilizes its skills in molecular biology, fermentation and protein engineering to produce Biologics in an affordable way, meeting global regulatory standards.

Gennova Biopharmaceuticals Ltd. is a biotechnology company based in Pune, Maharashtra, India. The company specializes in the research, development, production, and commercialization of biotherapeutics and vaccines aimed at treating life-threatening diseases in areas such as cardiovascular, neurology, nephrology, and oncology. Gennova employs advanced recombinant DNA technologies and innovative bio-manufacturing practices to create effective biotherapeutic solutions. The company utilizes various expression platforms, including bacterial, mammalian, and yeast-based systems, to produce its recombinant products. Gennova has successfully commercialized seven products, including Tenectase, a biosimilar for treating Acute Ischemic Stroke, and HAMSYL, a treatment for acute lymphoblastic lymphoma offered at a lower price point for better accessibility. With a strong focus on research and development, Gennova is recognized as a preferred partner in the vaccine sector for research and cGMP manufacturing. The company employs around 598 people and has reported a revenue of $2.8 million, positioning itself as a notable player in the Indian biotechnology landscape.

Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest-growing small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities. We are focused on meeting diverse injectables needs with a stable supply of affordable and high-quality products. We have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectables.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry. Equipped with a world-class infrastructure manned by best-in-class personnel & driven by the core values of knowledge, innovation and excellence, within a relatively short period, Laurus labs emerged as a segment-leading manufacturer of high quality APIs, a preferred partner for NCE development & manufacture & a trusted source of specialty ingredients for the nutraceutical industry. Given the strengths, capabilities & experience, Laurus Labs is uniquely positioned to help its clients in their endeavor of ‘quicker to market' & thus contributing towards improving access to quality & affordable healthcare worldwide.

Lazuline Biotech Private Limited is a research-driven and quality-focused biomanufacturer with a focus on improving the human health by catering to the needs of the healthcare and biopharma industries. Our world-class R&D and cGMP manufacturing facility in Hyderabad, India has enabled us to develop a range of Recombinant and Biological products. Founded in 2011, through the years we have been able to differentiate ourselves with our product-oriented focus and global partnerships. Through continuous innovations and single-pointed focus, we are proud to be producing the highest capacity in the world at economical pricing for the global market.

Meril's core objective is to design, manufacture and distribute clinically relevant, state-of-the-art and best-in-class medical devices to alleviate human suffering and improve quality of life. We thus have a strong commitment towards R & D and adherence to best quality standards in Manufacturing, Scientific Communication and Distribution known today. Origin Established in 2006, Meril was launched in line with the health-care diversification plan by a large format Indian multi-national company. Disclaimer: Information on Meril Digital / Social Media platform is not intended to be a substitute for professional medical advice, diagnosis or treatment. Meril does not recommend self-management of health issues. For more information, visit: https://www.merillife.com/disclaimer

Metrochem API is one of the fastest growing manufacturers of Active Pharmaceutical Ingredients (APIs), Pellets (Semi finished Formulations) and Intermediates in Multi Therapeutic segments like Antiulceratives, Antifungals, Antidepressants, Antihypertensives, AntiThrombotic, Antihistaminic, Antilipemic, Antiarthritic, Antiinflammatory, Antidiabetic, Antibacterial, Gastoprokinetic. We have total Six State- of- the-Art production facilities based in Hyderabad & Vishakapatnam, India. To cater our customer high volume requirements, we have dedicated each of our 6 manufacturing facilities to our 3 core product groups – APIs, Pelletization& Intermediates – reinforeced by a well equipped, centralized Research & Development laboratory. Our facilities are ISO 9001-2008, WHO: GMP, USFDA, Cofepris and Japanese Accredited approved. Inspected by KFDA authorities and awaiting for certification andmoving towards EUGMP, MHRA &TGA in 2015. Metrochem API management team having of top notch professionals, with extensive experience in Organic chemistry. Our most valuable resource is its people, It is a Knowledge driven company with dedicated professionals at the helm handling operations in Research & Development, Production, Quality Assurance, Marketing, Supply Chain and Finance.

M.J. Biopharm is a fully integrated biopharmaceutical company offering human insulin, analogue insulin, GLP1 agents, both as drug substance and formulations. M.J. offers partnering opportunities in development and commercialisation of generic products. Our process development expertise is from proof of concept to commercial scale and yield optimisation. We also offer contract manufacturing in vials, ampoules, cartridges and disposable pens. Contact email address: linkedin@mjbiopharm.com

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 22 state-of-the-art manufacturing facilities (15 API and 7 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly. Backed by a dedicated and experienced team of over 14,000 qualified professionals, the organization has earned a global distinction for its innovation, quality and speed of delivery besides achieving the following: > About 900+ national and international patent applications filed > Product portfolio of 450 + APIs & 300+ Finished Dosages > Over 35 major therapeutic offerings covering Oncology, Cardiology, CNS, Diabetes, Nephrology, Urology, Gastroenterology, Orthopaedics etc. > World No. 1 in active US DMF Filings > Won the trust of more than 40 Million patients across 100+ countries The organizational environment at MSN Labs integrates multiple disciplines and functions by effective implementation of goals and objectives through technology coupled with Integrity, Imagination and Innovation. The company's proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight-driven IT, and world-class facilities remain at the heart of its continuing success. We own a track record of growing at an exponential pace since our inception. From 22 Million USD in 2005 to achieving about 670 Million USD turnover in FY 2021-22 and counting, we continue to expand our growth and global footprint by creating innovative solutions for tomorrow's healthcare requirements.

NATCO Pharma is a vertically integrated company dedicated to the development, manufacture, and supply of pharmaceutical and agrochemical products. Established with the mission to make specialty medicines accessible to all, we are rooted in integrity, respect, openness, collaboration, creativity, and quality. Founded in 1981, we now have a strong global presence in over 50 countries. NATCO has emerged as an esteemed pharmaceutical company with a presence in Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) in both domestic and international markets. NATCO Pharma's focused approach has led to expanded capabilities across diverse therapy segments, particularly in oncology. We operate in two key segments: Pharmaceuticals and Agrochemicals. Our expertise excels in the FDF division, crafting intricate pharmaceutical solutions tailored to specific therapeutic needs. In the manufacturing of APIs, we maintain high quality and adhere to all regulatory standards with a focus on innovation. In the Crop Health Sciences (CHS) division, we produce high-value agricultural input products to meet farmers' demands, including environmentally safer biocontrol products. Operating globally, NATCO's work contributes to its diverse market presence. NATCO believes in sustainable and balanced growth through the synergy of our talented workforce and an innovative culture. We are dedicated to maximizing shareholder value creation through innovation, employee engagement, process and system optimization.

Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end chemistry-related solutions provider for the pharmaceutical industry. With three FDA-inspected facilities, 846+ DMFs, 1000+ employees and customers in more than 85 countries, Neuland supports some of the world's best-known and most successful pharmaceutical research and manufacturing companies. The spirit of research and professionalism pervades Neuland's corporate culture. Neuland's manufacturing capabilities and competence in complex chemistry provides reliable and superior quality products and services. Neuland is a leading manufacturer of APIs and provides customers with: * Contract research, contract manufacturing and generic APIs * 75 API's in 10 diverse therapeutic areas * 3 regulatory approved manufacturing facilities * 40,000 sq. ft. state-of-the-art R&D facility in Hyderabad * 300 + scientists working in R & D * Listed on the Bombay Stock Exchange and National Stock Exchange * Worldwide compliant facilities (WHO, US FDA, EMA, PMDA, TGA, KFDA, ANVISA, ISO 14001, ISO 27001 and OHSAS 18001 Certified) Neuland's core strategy is to never to compete with its customers. Neuland focuses purely on serving the global pharmaceutical firms with API manufacturing, and contract research & manufacturing services.

Orbicular Pharmaceutical Technologies Pvt. Ltd. is a Specialty Pharmaceutical Company that develops niche and complex pharmaceutical dosage forms for licensing to global partners. We are based out of Hyderabad, India and have a state-of-the-art Research facility of 100,000 sq. ft +, accommodating end-to-end capabilities for product delivery across entire product R&D lifecycle. We are a leading Research company backed by a strong team of 300+ competent scientists focussed on making us a one-stop shop to ensure seamless delivery of highly complex products. Our focus is on developing generic pharmaceutical product and 505(b)(2) products with complex chemistry, technological barriers, and limited competition for the global markets. We have extensive experience in developing cutting edge solutions, proprietary processes and technologies to deliver products across multiple delivery platforms, including nano-suspensions, nano-emulsions, liposomes, nanoparticles, and long-acting polymeric injectable suspensions. Our pipeline includes Complex Injectables, Topicals, Ophthalmics, Parenterals, Nasal Sprays /Inhalations and Complex Peptide combination products that target various treatment indications. Our pipeline is characteristic of product domain that is complex, has entry barriers and a is lucrative. We are an outcome driven and value generating organization creating growth partnerships for global pharma players across the entire spectrum of Complex Generics. Our vision is aptly captured in our tag line: Performance Excellence Delivered ! To know more about Orbicular Pharmaceutical Technologies, visit https://orbicular.co.in or reach out to us at hr.dept@orbicular.co.in!

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing. We today rank among the top 50 pharmaceutical companies in India and enjoy a multi-therapeutic presence across segments like anti-infectives, Our pharmaceutical solutions include active pharmaceutical ingredients (API), We are globally present across 40+ countries through alliances and partnerships with globally reputed majors. Our integrated business model enables us to cater to business opportunities throughout the value chain, from research to delivery of drugs across therapeutic segments. Our niche product basket helps us maintain an edge over our peers in the markets where we are present. In the years to come, driven by a highly competent and motivated team, we will move from strength to strength in the key domains of API, and global generics. On March 31, 2020, the resolution plan under CIRP has been implemented and the Board has been re-constituted with the members nominated by Dhanuka Laboratories Limited,

Oxford Pharmaceuticals is a pharmaceutical manufacturer specializing in generic oral solid tablets, operating a state-of-the-art facility with a focus on quality control and regulatory compliance.

PopVax is an Indian biotechnology company based in Hyderabad building a novel thermostable, low-cost, and safe second-generation mRNA platform for rationally-designed broadly-protective multi-epitope vaccines. We're starting with an open-source 4-8 °C refrigerator-stable booster candidate that is intended to protect against the entire sarbecovirus sub-family, including current and future strains of SARS-CoV-2 (the virus which causes COVID-19), and some other beta-coronaviruses such as MERS-CoV. PopVax's work has been funded primarily via collaboration with the Bill & Melinda Gates Foundation (India) and Vitalik Buterin's Balvi. Our India-based team of 30 researchers and senior manufacturing leaders includes experts in antigen design, mRNA sequence optimization and synthesis, and nucleic acid delivery from top Indian and North American research institutions, including CCMB, CDFD, IIT Delhi, IAVI, Harvard, Scripps, and UBC, as well as vaccine & biologics production veterans from companies including Sanofi, Biocon, Panacea Biotec and Biological E. The smaller scientific team for our US-based subsidiary, PopVax North America, is led by Moderna's first Director of Chemistry, and includes several leading practitioners of de novo computationally-driven rational protein design for novel vaccine immunogens.

Premas is developing transformational technologies and partnering with pharmaceutical companies around the world to expedite their drug discovery programs by cutting down significantly both on costs & time to clinics. Axtex-4D, a three-dimensional cell culture platform, engineered to produce high-throughput screens for targeted immuno-oncology drug candidates, is compelling scientists to relook at their tumor-targeting strategies. The ex-vivo culture systematically mirrors the in-vivo tumor microenvironment and is poised to revolutionize both drug discovery & combinatorial therapies. D-Crypt, a platform for 'difficult-to-express' proteins, is designed to considerably reduce time, cost, and risks associated with producing high-quality recombinant proteins. D-Crypt combines a yeast expression host with over 20 custom-made expression vectors. C-Qwence, our naive India-based Antibody Library is harnessing the power of a genetic pool that is more diverse than any other region and has exposures to infectious diseases and changes in an environment not seen in Europe or America. C-Qwence captures a wealth of novel genetics and protective immune responses, demonstrated in the unique profiles of individual antibodies isolated from the libraries. Combining our breakthrough technologies with state-of-the-art Gene to IND biologics development capabilities, Premas is seeking new partnerships with pharmaceutical companies to help accelerate the delivery of new medicines to patients.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

THINQ is a totally vertically integrated service and product provider for pharmaceutical companies offering the below services: - Contract R&D Contract Manufacturing - API Development, Manufacturing and Marketing - Formulation Development & Marketing

Vopec Pharmaceuticals Private Ltd. is a pioneering company which is manufacturing Ayurveda and siddha formulations, and was established in the year 1996. Vopec pharma has taken up a leading role in the formulations re-establishing ancient knowledge with modern Research and manufacturing techniques. The company is located in Aminjikarai, Chennai having GMP Certificate and FSSA licence to manufacture nutraceuticals. Vopec also have licence to manufacture Ayurvedic and Siddha formulations including Sasthric products and Food supplements. Vopec is a stake holder in Traditional Ayush Cluster of Tamilnadu (P) Ltd., precisely called TACT. Vopec Pharmaceuticals has various herbal capsules, syrups and pain relieving oils like Nart Capsule, Asmask Capsules, Dyzee Syrup etc. Another exciting program that Vopec provides are the consultation slots with Ayurveda experts, where one can mention their problems or issues and get effective solutions within minutes.

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.